NZ511608A - Pharmaceutical compositions comprising thiazolidinedione, insulin secretagogue and biguanide for treating diabetes - Google Patents
Pharmaceutical compositions comprising thiazolidinedione, insulin secretagogue and biguanide for treating diabetesInfo
- Publication number
- NZ511608A NZ511608A NZ511608A NZ51160898A NZ511608A NZ 511608 A NZ511608 A NZ 511608A NZ 511608 A NZ511608 A NZ 511608A NZ 51160898 A NZ51160898 A NZ 51160898A NZ 511608 A NZ511608 A NZ 511608A
- Authority
- NZ
- New Zealand
- Prior art keywords
- insulin secretagogue
- biguanide
- thiazolidinedione
- pharmaceutical compositions
- insulin
- Prior art date
Links
- 229940122199 Insulin secretagogue Drugs 0.000 title abstract 3
- 229940123208 Biguanide Drugs 0.000 title abstract 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title 1
- 229940123464 Thiazolidinedione Drugs 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 231100000489 sensitizer Toxicity 0.000 abstract 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 abstract 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 abstract 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 abstract 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001466 acetohexamide Drugs 0.000 abstract 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 abstract 1
- 229960003362 carbutamide Drugs 0.000 abstract 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001761 chlorpropamide Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 229960001764 glibornuride Drugs 0.000 abstract 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 abstract 1
- 229960000346 gliclazide Drugs 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- 229960001381 glipizide Drugs 0.000 abstract 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
- 229960003468 gliquidone Drugs 0.000 abstract 1
- 229950008402 glisentide Drugs 0.000 abstract 1
- NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 abstract 1
- 229950005319 glisolamide Drugs 0.000 abstract 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003236 glisoxepide Drugs 0.000 abstract 1
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical group COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002354 repaglinide Drugs 0.000 abstract 1
- 229960002277 tolazamide Drugs 0.000 abstract 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 abstract 1
- 229960005371 tolbutamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9715295A GB9715295D0 (en) | 1997-07-18 | 1997-07-18 | Novel method of treatment |
| NZ501164A NZ501164A (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with a thiazolidinedione, an insulin secretagogue and a biguanide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ511608A true NZ511608A (en) | 2002-12-20 |
Family
ID=10816167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ501164A NZ501164A (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with a thiazolidinedione, an insulin secretagogue and a biguanide |
| NZ511608A NZ511608A (en) | 1997-07-18 | 1998-07-16 | Pharmaceutical compositions comprising thiazolidinedione, insulin secretagogue and biguanide for treating diabetes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ501164A NZ501164A (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with a thiazolidinedione, an insulin secretagogue and a biguanide |
Country Status (39)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| ID28783A (id) * | 1998-11-12 | 2001-07-05 | Smithkline Beecham Plc | Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain |
| SE9902918D0 (sv) * | 1999-08-13 | 1999-08-13 | Pharmacia & Upjohn Ab | Methods for identification of compounds stimulating insulin secretion |
| AR030920A1 (es) | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
| WO2001035940A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| FR2812547B1 (fr) * | 2000-08-04 | 2002-10-31 | Lipha | Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete |
| PL362687A1 (en) | 2001-01-12 | 2004-11-02 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
| ITFI20010126A1 (it) * | 2001-07-09 | 2003-01-09 | Molteni & C | Composizioni farmaceutiche per uso orale,contenenti,in combinazione,metformina e gliclazide |
| AU2001273289B2 (en) * | 2001-07-10 | 2004-10-07 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
| WO2003105809A1 (en) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| WO2004026241A2 (en) * | 2002-09-20 | 2004-04-01 | Andrx Labs Llc | Multistage formulation containing a biguanide and thiazolidindione derivatives |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| BRPI0414979A (pt) | 2003-10-31 | 2006-11-21 | Takeda Pharmaceutical | preparação sólida |
| MXPA05010977A (es) * | 2005-10-12 | 2007-04-11 | Abdala Leopoldo Espinosa | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus. |
| KR100812538B1 (ko) * | 2006-10-23 | 2008-03-11 | 한올제약주식회사 | 약물 제어방출형 메트포르민-글리메피리드 복합제제 |
| CN101417130B (zh) * | 2007-10-22 | 2010-10-06 | 鲁南制药集团股份有限公司 | 一种治疗ⅱ型糖尿病及其并发症的药物组合物 |
| KR102176069B1 (ko) * | 2017-10-20 | 2020-11-09 | 주식회사 노브메타파마 | 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
| JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| US4582839A (en) * | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
| CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| JPH06779B2 (ja) * | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
| US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
| US4791125A (en) * | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
| WO1989008651A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
| US5061717A (en) * | 1988-03-08 | 1991-10-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| WO1991007107A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
| JPH04210683A (ja) * | 1990-12-06 | 1992-07-31 | Terumo Corp | チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬 |
| WO1993003724A1 (en) * | 1991-08-26 | 1993-03-04 | The Upjohn Company | Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride |
| US5917052A (en) * | 1994-09-28 | 1999-06-29 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| EP2266576A1 (en) * | 1997-06-18 | 2010-12-29 | SmithKline Beecham Limited | Treatment of diabetes with thiazolidinedione and sulphonylurea |
-
1997
- 1997-07-18 GB GB9715295A patent/GB9715295D0/en active Pending
-
1998
- 1998-07-15 DZ DZ980172A patent/DZ2562A1/xx active
- 1998-07-16 BR BR9810445-4A patent/BR9810445A/pt not_active Application Discontinuation
- 1998-07-16 TR TR2000/00134T patent/TR200000134T2/xx unknown
- 1998-07-16 HU HU0003629A patent/HUP0003629A3/hu unknown
- 1998-07-16 CA CA002296653A patent/CA2296653C/en not_active Expired - Fee Related
- 1998-07-16 MA MA25171A patent/MA24607A1/fr unknown
- 1998-07-16 IL IL13404698A patent/IL134046A0/xx unknown
- 1998-07-16 UA UA2000010261A patent/UA70303C2/uk unknown
- 1998-07-16 SK SK59-2000A patent/SK285484B6/sk not_active IP Right Cessation
- 1998-07-16 PL PL338126A patent/PL197844B1/pl not_active IP Right Cessation
- 1998-07-16 AP APAP/P/2000/001733A patent/AP1352A/en active
- 1998-07-16 DK DK98935127T patent/DK1001783T3/da active
- 1998-07-16 JP JP2000502776A patent/JP2001510159A/ja not_active Withdrawn
- 1998-07-16 KR KR1020007000512A patent/KR100671918B1/ko not_active Expired - Fee Related
- 1998-07-16 SI SI9830804T patent/SI1001783T1/sl unknown
- 1998-07-16 PL PL378474A patent/PL198017B1/pl not_active IP Right Cessation
- 1998-07-16 EA EA200000139A patent/EA003021B1/ru not_active IP Right Cessation
- 1998-07-16 NZ NZ501164A patent/NZ501164A/en unknown
- 1998-07-16 ES ES98935127T patent/ES2251093T3/es not_active Expired - Lifetime
- 1998-07-16 EP EP98935127A patent/EP1001783B1/en not_active Expired - Lifetime
- 1998-07-16 DE DE69831808T patent/DE69831808T2/de not_active Expired - Fee Related
- 1998-07-16 WO PCT/GB1998/002110 patent/WO1999003477A1/en not_active Ceased
- 1998-07-16 ID IDW20000075A patent/ID24211A/id unknown
- 1998-07-16 AU AU84488/98A patent/AU8448898A/en not_active Abandoned
- 1998-07-16 CN CN98807319A patent/CN1264303A/zh active Pending
- 1998-07-16 AR ARP980103481A patent/AR016349A1/es unknown
- 1998-07-16 NZ NZ511608A patent/NZ511608A/xx unknown
- 1998-07-16 AT AT98935127T patent/ATE305790T1/de not_active IP Right Cessation
- 1998-07-16 PE PE1998000629A patent/PE99599A1/es not_active Application Discontinuation
- 1998-07-17 CO CO98040747A patent/CO4940420A1/es unknown
- 1998-07-17 ZA ZA9806363A patent/ZA986363B/xx unknown
- 1998-07-17 MY MYPI98003288A patent/MY155219A/en unknown
- 1998-07-17 UY UY25102A patent/UY25102A1/es not_active IP Right Cessation
- 1998-07-17 TW TW087111770A patent/TW505516B/zh active
- 1998-07-20 IN IN2087DE1998 patent/IN189275B/en unknown
- 1998-08-29 SA SA98190468A patent/SA98190468B1/ar unknown
-
2000
- 2000-01-17 NO NO20000228A patent/NO325727B1/no not_active IP Right Cessation
- 2000-01-18 OA OA1200000012A patent/OA11279A/en unknown
- 2000-02-07 BG BG104135A patent/BG64785B1/bg unknown
-
2005
- 2005-04-21 JP JP2005123562A patent/JP2005213273A/ja active Pending
- 2005-12-07 CY CY20051101486T patent/CY1105254T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ511608A (en) | Pharmaceutical compositions comprising thiazolidinedione, insulin secretagogue and biguanide for treating diabetes | |
| NZ501260A (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| AU777776B2 (en) | Use of hypoglycemic agent for treating impaired glucose metabolism | |
| NZ334580A (en) | Sibutramine analogues to prevent the development of diabetes | |
| UY24893A1 (es) | Combinaciones para diabetes de sulfonilurea glitazona | |
| EP1128834A1 (en) | Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide | |
| JP2004155791A (ja) | 新規ｎｉｄｄｍ療法 | |
| AR057970A2 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones | |
| Kiayias et al. | Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients | |
| AR015894A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos | |
| MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
| CA2297115A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| NZ513922A (en) | Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione | |
| UY25101A1 (es) | Método para el tratamiento de la diabetes mellitus y las condiciones asociadas | |
| UY25048A1 (es) | Composiciones para el tratamiento de la diabetes mellitus | |
| KR20010075698A (ko) | 베타 아고니스트 및 추가의 항당뇨병제를 포함하는 병용제 | |
| TH21456B (th) | กรรมวิธีในการรักษาเบาหวานด้วยไธอะโซลิดีนไดโอนและซัลโฟนิลยูเรีย | |
| AP1841A (en) | A thiazolidinedione derivative and its use as antidiabetic. | |
| TH36757A (th) | กรรมวิธีในการรักษาเบาหวานด้วยไธอะโซลิดีนไดโอนและซัลโฟนิลยูเรีย | |
| Quinn | Pharmacologic management of the patient with type 2 diabetes | |
| Mikhail | Semaglutide: The First Oral Glucagon-like Peptide 1 Agonist | |
| MXPA00000631A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| EA002659B1 (ru) | Применение 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона для лечения гипергликемии | |
| MXPA01004826A (en) | Combinations comprising a beta-agonist and a further antidiabetic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |